Search

Your search keyword '"Hirsch, Ian"' showing total 184 results

Search Constraints

Start Over You searched for: Author "Hirsch, Ian" Remove constraint Author: "Hirsch, Ian"
184 results on '"Hirsch, Ian"'

Search Results

1. Risk of COVID-19 after natural infection or vaccination.

2. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

4. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

6. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

7. Risk of COVID-19 after natural infection or vaccination

9. COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials

12. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

13. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

18. Risk of COVID-19 after natural infection or vaccination

19. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

21. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre

22. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre

24. Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study

27. Cáncer de ovario de células transicionales

29. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

31. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

32. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

33. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

35. Benefit–risk assessment in a post-market setting: a case study integrating real-life experience into benefit–risk methodology†

37. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

38. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

39. Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

48. Benralizumab treatment and SARP cluster analysis

Catalog

Books, media, physical & digital resources